GC Green Cross Lab Cell(116,300 -4.36%)Announced on the 2nd that it has obtained a patent for a substance and composition for the’chimeric antigen receptor (CAR) signaling domain’ from the Australian Patent Office.
It is a patent for a technology that enhances the efficacy of natural killer (NK) cells through the CAR signaling domain.
NK cells are innate immune cells that immediately attack cancer cells or abnormal cells in the body. The CAR signaling domain serves to transmit a strong signal to activate NK cells.
A typical CAR signaling domain is a way to activate T cells. GC Green Cross Lab Cell succeeded in self-development in a method specialized in NK cell activation. This explains that the survival period of NK cells in the body is prolonged and the potency is very high.
This patent is one of the platform technologies that GC Green Cross Labcell recently signed with MSD to export the technology of about KRW 2 trillion.
According to the company, CAR-NK cell therapy, which combines NK cells and CAR cells, is being developed as a next-generation anticancer drug. It is explained that the safety is superior to that of a few commercially available next-generation anticancer drugs. It can also be mass-produced in ready-made form, so it can be used by others.
In fact, GC Green Cross Lab Cell has confirmed excellent cancer cell killing effects in animal experiments with the next-generation CAR-NK cell therapy drug (HER2-CAR-NK) to which this technology is applied.
Hwang Yoo-kyung, head of GC Green Cross Lab Cell Cell Therapy Research Institute, said, “We are continuing to capitalize on the core technology for the development of next-generation NK cell treatments at home and abroad.”
Reporter Park In-hyuk [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution